H.Lundbeck Korea eye CNS market in Korea

Published: 2002-09-16 06:58:00

Updated: 2002-09-16 06:58:00

H.Lundbeck A/S, a renowned CNS drug maker in the world, has finally entered the Korean market with a firm strategy to expand their presence in the domestic CNS market within the next three years under strategic alliances with Whanin Pharm.

In his press interview, president Ole Steen Antonsen ...

Fees

- Email service daily and homepage access.

$300 per month. ($3,240 per year)
5 Email holders per each company.
Anual contract base.

Latest News

Which are outstanding tetravalent vaccines even for the young?

Disease treated the most with clinical trial drugs is respiratory disorder like lung cancer

Who will be the next Pharmaceutical Safety Bureau Director?

Celltrion completes clinical trials for Remsima SC for European approval

Sales listed pharmas made in the first half of the year

TOP

BACK